{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:08:24Z","timestamp":1761844104172,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.urolonc.2010.12.004","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T17:56:45Z","timestamp":1311875805000},"page":"198-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Low-dose diethylstilbestrol for the treatment of advanced prostate cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Julia","family":"Clemons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Michael","family":"Glod\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2010.12.004_bib1","first-page":"293","article-title":"Studies on prostate cancer; the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2010.12.004_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-5347(17)62926-4","article-title":"Carcinoma of the prostate: Treatment comparisons","volume":"98","year":"1967","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","article-title":"Leuprolide vs. diethylstilbestrol for metastatic prostate cancer","volume":"311","author":"Garnick","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2010.12.004_bib4","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C","article-title":"The Veterans Administration Cooperative Urological Research Group's studies of carcinoma of the prostate","volume":"32","author":"Byar","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2010.12.004_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO;2-9","article-title":"Estrogen treatment for cancer of the prostate. Early results with three doses of diethylstilbestrol and placebo","volume":"26","author":"Bailar","year":"1970","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2010.12.004_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000475067","volume":"28","author":"Robinson","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0090-4295(98)00173-3","article-title":"A phase II trial of oral diethylstilbestrol as a second line hormonal agent in advanced prostate cancer","volume":"52","author":"Smith","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2010.12.004_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000087797","article-title":"Diethylstilbestrol versus bicalutamide in hormone refractory prostate cancer: A prospective randomized trial","volume":"75","author":"Manikandan","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2010.12.004_bib9","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/cncr.25194","article-title":"A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer","volume":"116","author":"Shamash","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2010.12.004_bib10","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.3816\/CGC.2009.n.027","article-title":"The mechanism of action of estrogen in castration-resistant prostate cancer: Clues from hormone levels","volume":"7","author":"Aggarwal","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2010.12.004_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0090-4295(01)01252-3","article-title":"The role of diethylstilbestrol in the treatment of prostate cancer","volume":"58","author":"Malkowitz","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2010.12.004_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bmj.4.5784.391","article-title":"Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma","volume":"4","author":"Robinson","year":"1971","journal-title":"Brit Med J"},{"key":"10.1016\/j.urolonc.2010.12.004_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jsbmb.2005.05.004","article-title":"Treatment with high dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients","volume":"96","author":"Geisler","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jsbmb.2005.02.012","article-title":"Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOP","volume":"96","author":"Kalach","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/1471-2407-10-244","article-title":"Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer","volume":"10","author":"Montgomery","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2010.12.004_bib16","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/pros.21166","article-title":"The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells","volume":"70","author":"Geier","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2010.12.004_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jnci\/88.13.908","article-title":"Induction of apoptosis by diethylstilbestrol on hormone insensitive prostate cancer cells","volume":"88","author":"Robertson","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2010.12.004_bib18","first-page":"5008","article-title":"Role of the mitochondrial bc1-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells","volume":"50","author":"Schulz","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2010.12.004_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2008.10.035","article-title":"The evolving role of oestrogens and their receptors in the development and progression of prostate cancer","volume":"55","author":"Bonkhoff","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1749-6632.2009.04360.x","article-title":"The dual, opposing roles of estrogen in the prostate","volume":"1155","author":"Ellem","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.urolonc.2010.12.004_bib21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/aja.2010.14","article-title":"Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor","volume":"12","author":"Wang","year":"2010","journal-title":"Asian J Androl"},{"key":"10.1016\/j.urolonc.2010.12.004_bib22","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(10)70038-3","article-title":"Risk of thromboembolic diseases in men with prostate cancer: Results from the population-based PCBaSe Sweden","volume":"11","author":"Van Hemelrijck","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib24","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2004.10.195","article-title":"Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer","volume":"22","author":"Oh","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(09)60205-1","article-title":"Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): An open-label randomized trial","volume":"373","author":"Young","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2010.12.004_bib26","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/01.ju.0000077558.48257.3d","article-title":"The nonsteroidal effects of diethylstilbestrol: The rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer","volume":"170","author":"Scherr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mdp112","article-title":"Diethylstilbestrol retains activity and is a reasonable option in patients previously treated with docetaxel for castration resistant prostate cancer","volume":"20","author":"Serrate","year":"2009","journal-title":"Annals Oncol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6604052","article-title":"Re-induction of hormone sensitivity to diethylstilbestrol in androgen refractory prostate cancer patients following chemotherapy","volume":"98","author":"Cox","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2010.12.004_bib29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22811","article-title":"Activity of second-line chemotherapy in docetaxel-refractory hormone refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone","volume":"110","author":"Rosenberg","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2010.12.004_bib30","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Anti-androgen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB)","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.12.004_bib31","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/cncr.21799","article-title":"Androgen-deprivation therapy as primary treatment for localized prostate cancer: Data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)","volume":"106","author":"Kawakami","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2010.12.004_bib32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation anti-androgen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2010.12.004_bib33","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910003911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910003911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:59:32Z","timestamp":1761040772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143910003911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1078143910003911"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.12.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose diethylstilbestrol for the treatment of advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}